Pediatric dermatoses pattern at a Brazilian reference center

Miotto, Isadora Zago; Bessa, Vanessa Rolim; Vasconcelos, Luana Barreto de Almeida; Samorano, Luciana Paula; Machado, Maria Cecília Rivitti; Oliveira, Zilda Najjar Prado de

doi:10.1016/j.jped.2020.02.002

Cited by 9 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty‐eight 9,12–15,17,20,21,24,30–58 (65.5%) articles reported on incidence covering 22 (264,254,023) countries. Twenty‐five 14,22,23,54–75 (43.1%) reported on prevalence covering 20 ( n = 107,005,322) countries, and 6 14,54–58 (10.3%) on both incidence and prevalence covering 6 countries. The observational period varied from 1 year 54 to 50 years 30 .…”

Section: Resultsmentioning

confidence: 99%

“…Among articles on incidence, there were 21 (51.2%) articles for Europe, 9,14,15,20,21,24,32–37,41–44,48–50,54,58 12(30.8%) for Asia, 12,13,17,31,39,40,45,47,51–53,57 3(10.3%) for North America, 30,38,46 and 2 for Africa 55,56,58 . With regard to prevalence‐related articles, there were 12 (48%) articles for Asia, 57,59,60,62,63,65,68–72,75 7(28%) for Europe, 14,22,54,58,64,66,73 3(12%) for Africa, 23,55,56 and 1(4%) for South Africa, 67 North America, 74 and Oceania, 61 respectively. Nineteen 23,54–56,59–72 (76%) studies used clinic‐based data, and 6 14,22,57,58,73,74 (24%) used population‐based data.…”

Section: Resultsmentioning

confidence: 99%

“…With regard to prevalence‐related articles, there were 12 (48%) articles for Asia, 57,59,60,62,63,65,68–72,75 7(28%) for Europe, 14,22,54,58,64,66,73 3(12%) for Africa, 23,55,56 and 1(4%) for South Africa, 67 North America, 74 and Oceania, 61 respectively. Nineteen 23,54–56,59–72 (76%) studies used clinic‐based data, and 6 14,22,57,58,73,74 (24%) used population‐based data. A summary of all included studies is given in Tables 1 and 2, the sample size ranged from 28 to 80,925,000.…”

Section: Resultsmentioning

confidence: 99%

“…Clinic-based studies on prevalence were more widely spread across the world, 19 (76%) articles included in this subgroup, one from South Africa 67 and Oceania, 61 three from Africa 23,55,56 and Europe, 54,64,66 11 from Asia. 59,60,62,63,65,[68][69][70][71][72]75 The clinic-based prevalence varied between 0.013% and 15.7%.…”

Section: Prevalence Of Bpmentioning

confidence: 98%

“…Nineteen 23,[54][55][56][59][60][61][62][63][64][65][66][67][68][69][70][71][72] (76%) studies used clinic-based data, and 6 14,22,57,58,73,74 (24%) used population-based data. A summary of all included studies is given in Tables 1 and 2, the sample size ranged from 28 to 80,925,000.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Global incidence and prevalence of bullous pemphigoid: A systematic review and meta‐analysis

Chen

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Integrated information on the global prevalence and incidence of bullous pemphigoid (BP) is lacking. Objective To estimate the incidence and prevalence of BP in a systematic review and meta‐analysis. Methods Observational studies were included by using databases of Medline, EMBASE, and Cochrane Library. Subgroup analysis was by continent, age, sex, and country income level. Random‐effects model was used. Between‐study heterogeneity was assessed using the I2 statistic. Results The global incidence was 0.0419 per 1000 person‐years (95% CI: 0.0414–0.0424). The incidence was 0.047 per 1000 person‐years (95% CI: 0.0462–0.0477), 0.0419 per 1000 person‐years (95% CI: 0.0411–0.0426), 0.0072 per 1000 person‐years (95% CI: 0.0067–0.0078), 0.003 per 1000 person‐years (95% CI: 0.0023–0.0039) in North America, Europe, Asia, and Africa, respectively; 0.0202 per 1000 person‐years (95% CI: 0.0196–0.0208) and 0.0181 per 1000 person‐years (95% CI: 0.0175–0.0188) females and males; 0.001 per 1000 person‐years (95% CI: 0.001–0.001), 0.002 per 1000 person‐years (95% CI: 0.001–0.002), 0.004 per 1000 person‐years (95% CI: 0.004–0.004); 0.007 per 1000 person‐years (95% CI: 0.007–0.008), 0.011 per 1000 person‐years (95% CI: 0.011–0.012), 0.017 per 1000 person‐years (95% CI: 0.015–0.018) for age <50, 50–59, 60–69, 70–79, 80–89, and ≥90 years; 0.0038 per 1000 person‐years (95% CI: 0.0036–0.004112) (I2 = 99%, p < .05) and 0.0456 per 1000 person‐years (95% CI: 0.0450–0.0462) (I2 = 100%, p < .05). The pooled clinic‐based prevalence was 0.79% (95% CI: 0.75%–0.84%), 1.13% (95% CI: 1.06%–1.21%), 0.21% (95% CI: 0.17%–0.26%), and 0.13% (95% CI: 0.1%–0.15%) for Asia, Africa, and Europe. Conclusions This study identified the global incidence and prevalence of BP in terms of spatial and population distributions and among various income level. A relatively higher incidence was in Europe, females, older people, and high‐income level country. The prevalence was higher in Asia. These findings should be interpreted with caution due to high heterogeneity of included studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Prevalence Of Bpmentioning

confidence: 98%

Section: Characteristics Of Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Global incidence and prevalence of bullous pemphigoid: A systematic review and meta‐analysis

Chen

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

Alopecia Areata in Latin America: Where are We and Where are We Going?

Velásquez‐Lopera

Mantilla

Jansen³

et al. 2022

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Alopecia areata (AA) represents an underrecognized burden in Latin America (LA), severely impacting quality of life (QoL). This impact is exacerbated by limited access to specialized dermatologic care and therapies for AA within and among nations. Many of the unmet needs for AA globally also exist in LA. The region has geographic, ethnic, cultural, and economic conditions. With new AA medicines targeting immunologic pathways on the horizon, LA must prepare regarding regulatory issues, reimbursement, awareness, and education to give adequate and timely treatment for patients with AA. To address these issues, the Americas Health Foundation convened a panel of six dermatologists from Argentina, Brazil, Colombia, and Mexico who are experts in AA and its comorbidities for a 3-day virtual meeting to discuss AA diagnosis and treatment in LA and create a manuscript offering recommendations to address discussed barriers. This publication examines unmet AA needs in LA, treatment, and innovative therapies and recommends improving AA care. Access constraints to conventional and novel medicines hinder appropriate treatments for patients. Therapy initiation delays can affect QoL, mental health, and disease progression. People with AA face stigmas, discrimination, and misconceptions owing to a lack of disease awareness. With promising new treatments for AA on the horizon, all stakeholders must coordinate efforts to enhance LA’s AA management landscape and improve patient outcomes.

show abstract

Clinicoepidemiology of Skin Diseases in Children Seen at the University Hospital Center Morafeno, Toamasina, Madagascar

Ranaivo

Sendrasoa

Andrianarison

et al. 2021

Dermatology Research and Practice

View full text Add to dashboard Cite

Introduction. The child’s skin diseases are common and very diverse. Many studies concerning pediatric dermatoses have been carried out in Africa and the rest of the world. Few epidemioclinical data reflect these skin diseases in children, especially in the east coast of Madagascar. We aim to describe the pattern skin diseases among children seen at the University Hospital Center Morafeno, Toamasina, Madagascar. Patients and Methods. A retrospective study over a 3-year period from January 2017 to December 2019 was conducted in children seen in the Dermatology Department of University Hospital Center Morafeno, Toamasina, with skin diseases. Results. During the study period, 347 children out of the 1584 new patients were retained with a sex ratio of 0.86. The mean age was 6.4 years old. The main diseases identified were skin infectious diseases (43, 23%), allergic dermatoses (24.21%), and autonomous dermatosis (15.56%). Conclusion. Our study revealed the importance of infectious and allergic dermatoses in Toamasina. It is necessary to carry out simple preventive actions such as hygiene.

show abstract

Pediatric dermatoses pattern at a Brazilian reference center

Cited by 9 publications

References 26 publications

Global incidence and prevalence of bullous pemphigoid: A systematic review and meta‐analysis

Global incidence and prevalence of bullous pemphigoid: A systematic review and meta‐analysis

Alopecia Areata in Latin America: Where are We and Where are We Going?

Clinicoepidemiology of Skin Diseases in Children Seen at the University Hospital Center Morafeno, Toamasina, Madagascar

Contact Info

Product

Resources

About